Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow transplantation.

A Tyndall1, S Millikan

  • 1University Department of Rheumatology, Felix Platter Spital, Basel, Switzerland.

Bailliere'S Best Practice & Research. Clinical Rheumatology
|February 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Optimized 3D-SPACE and 3D-TSE Sequences at 1.5T MRCP in the Diagnosis of Choledocholithiasis.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin·2015
Same author

Clinical and experimental scleroderma 2014.

Clinical and experimental rheumatology·2014
Same author

Response to: 'Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?' by Jan Damoiseaux.

Annals of the rheumatic diseases·2014
Same author

Sicca symptoms and their impact on quality of life among very long-term survivors after hematopoietic SCT.

Bone marrow transplantation·2013
Same author

Temporal artery compression sign--a novel ultrasound finding for the diagnosis of giant cell arteritis.

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2012
Same author

[Stem cell treatment of autoimmune disease].

Deutsche medizinische Wochenschrift (1946)·2011
Same journal

Preface

Bailliere's best practice & research. Clinical rheumatology·2000
Same journal

Index

Bailliere's best practice & research. Clinical rheumatology·2000
Same journal

How do we manage chronic pain?

Bailliere's best practice & research. Clinical rheumatology·2000
Same journal

The biopsychosocial model--a tool for rheumatologists.

Bailliere's best practice & research. Clinical rheumatology·2000
Same journal

The psychology of rheumatic diseases.

Bailliere's best practice & research. Clinical rheumatology·2000
Same journal

Physical therapy and rehabilitation in the management of rheumatic disorders.

Bailliere's best practice & research. Clinical rheumatology·2000
See all related articles

Hematopoietic stem cell transplantation (HSCT) shows promise for treating severe autoimmune diseases like rheumatoid arthritis by resetting the immune system. While early results are encouraging, further clinical trials are needed to optimize this potentially curative therapy.

Area of Science:

  • Immunology
  • Rheumatology
  • Hematology

Background:

  • Severe autoimmune diseases, such as rheumatoid arthritis, often necessitate immunosuppression.
  • Haematoablation is a significant risk associated with immunosuppressive therapies.
  • Haematopoietic stem cell transplantation (HSCT) offers a method to rescue patients after high-dose immunosuppressive drugs.

Purpose of the Study:

  • To review the evolving role of HSCT in treating autoimmune diseases, particularly rheumatoid arthritis.
  • To discuss early clinical results and ongoing challenges in using HSCT for autoimmune conditions.
  • To explore strategies for future clinical trials and treatment optimization.

Main Methods:

  • Review of case reports and clinical data on HSCT for rheumatoid arthritis and other autoimmune diseases.

Related Experiment Videos

  • Analysis of animal model research supporting HSCT efficacy in autoimmune settings.
  • Summary of recent applications of HSCT in approximately 180 patients with autoimmune diseases.

    • Main Results:

    • Case reports indicate long-lasting improvement in rheumatoid arthritis following HSCT for other indications.
    • Recent application of HSCT in autoimmune diseases shows encouraging early results.
    • Approximately 180 patients have received HSCT for autoimmune diseases in the last three years, including rheumatoid arthritis and juvenile idiopathic arthritis.

    Conclusions:

    • HSCT is an emerging treatment for severe autoimmune diseases, with early data suggesting potential for long-term remission.
    • Further co-ordinated clinical trials are essential to clarify optimal treatment protocols and confirm efficacy.
    • Addressing remaining questions through rigorous research is crucial for establishing HSCT as a standard therapy for autoimmune arthritis.